8-K: Personalis Q3 2025: Clinical Growth Amidst Revenue Decline

Personalis, Inc. reported a 44% year-over-year revenue decrease in Q3 2025 to $14.5 million, driven by expected declines, but saw a 364% surge in clinical test volume for its NeXT Personal platform.

Summary

• Q3 2025 revenue was $14.5 million, a 44% decrease from $25.7 million in Q3 2024.
• Clinical test volume reached 4,388, marking a 26% sequential increase over Q2 2025 and 364% year-over-year growth, driven by physician adoption of the NeXT Personal platform.
• Gross margin declined to 13.2% in Q3 2025 from 34.0% in Q3 2024, primarily due to lower revenue volume and increased unreimbursed clinical test costs.
• Net loss for Q3 2025 was $21.7 million, or $0.24 per share, compared to a net loss of $39.1 million ($0.64 per share) in Q3 2024, which included a $26.0 million non-cash warrant expense.
• Cash, cash equivalents, and short-term investments stood at $150.5 million as of September 30, 2025, with $23.4 million cash usage from operations and capital equipment additions in the quarter.
• Full-year 2025 revenue guidance was reduced to a range of $68.0 to $73.0 million from the prior guidance of $70.0 to $80.0 million.
• Full-year 2025 clinical tests reimbursed revenue guidance was significantly reduced to $1.5 to $2.0 million from $3.0 to $6.0 million, anticipating a reimbursement milestone later in 2025.

Sentiment

Score: 4

Explanation: While clinical adoption and data are strong positives, the significant revenue decline, sharp drop in gross margin, and reduced full-year guidance, particularly for reimbursed clinical tests, indicate substantial financial challenges and delays in commercialization. The high cash burn rate also raises concerns.

Positives

• Achieved significant 364% year-over-year growth in clinical test volume, delivering 4,388 tests, indicating robust physician enthusiasm and adoption of the NeXT Personal platform.
• Presented positive new data from AstraZeneca's Phase 3 NeoADAURA trial, demonstrating NeXT Personal as a strong predictor of patient outcomes and a more sensitive and accurate measure of MRD in lung cancer.
• Data from the LAURA trial showed NeXT Personal could detect recurrence 5 months ahead of blinded expert review and could be utilized for treatment response monitoring in adjuvant lung cancer.
• Submitted a third dossier for Medicare coverage for lung cancer, expressing confidence in meeting the standard for coverage.
• Launched the CATE clinical trial in collaboration with Yale Cancer Center to demonstrate the utility of NeXT Personal in guiding treatment decisions for HR+/HER2breast cancer.

Negatives

• Total revenue decreased by 44% year-over-year to $14.5 million in Q3 2025.
• Population sequencing revenue saw a substantial 95% decrease year-over-year to $0.2 million.
• Gross margin significantly declined to 13.2% in Q3 2025 from 34.0% in Q3 2024, primarily due to lower revenue volume and increased unreimbursed clinical test costs.
• Full-year 2025 total revenue guidance was reduced from $70.0-$80.0 million to $68.0-$73.0 million.
• Full-year 2025 clinical tests reimbursed revenue guidance was substantially cut from $3.0-$6.0 million to $1.5-$2.0 million.
• Net loss of $21.7 million in Q3 2025, while lower than the reported prior year, is effectively worse when adjusting for the $26.0 million non-cash warrant expense in Q3 2024.
• Cash usage from operations and capital equipment additions amounted to $23.4 million in Q3 2025.

Risks

• The timing and pace of new orders from customers, including biopharma partners like ModernaTX, Inc. and Merck Sharp & Dohme LLC, are uncertain.
• Revenue guidance is dependent on the timing of tissue, blood, and other specimen sample receipts from customers.
• Challenges exist in establishing medical necessity for tests and securing adequate reimbursement rates from Medicare or other payers on expected timelines, or at all.
• Failure to secure Medicare reimbursement coverage for two indications this year could negatively impact clinical test revenue and overall revenue guidance.
• Future clinical data may differ from previously presented or expected results, potentially affecting the perceived value of the NeXT platform.
• Maintaining the accelerated physician adoption rates experienced in Q3 2025 for the NeXT platform is not guaranteed.
• The business is susceptible to the impact of competition and macroeconomic factors.
• Partnering and collaboration arrangements may not be successful or could terminate, adversely affecting business or the ability to develop and commercialize services and products.
• Reliance on a limited number of suppliers poses a risk.
• Customer concentration could impact revenue stability.

Future Outlook

Personalis expects Q4 2025 total revenue to be in the range of $15.7 to $20.7 million. For the full year 2025, total company revenue guidance has been updated to $68.0 to $73.0 million, a reduction from prior guidance. Revenue from clinical tests reimbursed is now expected to be $1.5 to $2.0 million, reduced due to an anticipated reimbursement milestone occurring later in 2025. Full-year gross margin is projected at 22% to 24%, with a net loss of approximately $85 million and cash usage of approximately $75 million, consistent with previous guidance for these latter metrics.

Management Comments

• "Our third-quarter results demonstrate clear progress in our strategy to Win-in-MRD."
• "The 364% year-over-year growth in our clinical test volume is a powerful indicator of physician enthusiasm for NeXT Personal."
• "We believe the compelling data from the AstraZeneca NeoADAURA and LAURA studies and the launch of our CATE trial with Yale are helping to build an unimpeachable evidence base for our technology."
• "With our third indication submitted for Medicare coverage, we are well positioned for success in this large market."

Industry Context

Personalis operates in the precision oncology and advanced genomics sector, focusing on minimal residual disease (MRD) detection. The significant year-over-year growth in clinical test volume for its NeXT Personal platform suggests increasing adoption of personalized cancer monitoring solutions, aligning with a broader industry trend towards precision medicine and early detection. The pursuit of Medicare coverage for lung cancer indications highlights the company's efforts to penetrate a large, established market, a common strategy for diagnostic companies seeking broader commercialization. The collaboration with AstraZeneca and Yale Cancer Center underscores the importance of clinical validation and partnerships in this competitive and rapidly evolving field.

Comparison to Industry Standards

• The 364% year-over-year growth in clinical test volume for NeXT Personal is exceptionally high and suggests strong market penetration for a novel diagnostic, potentially outperforming typical growth rates for established diagnostic platforms.
• The reported ability of NeXT Personal to detect recurrence 5 months ahead of blinded expert review in the LAURA trial sets a high bar for sensitivity and timeliness in MRD detection, potentially positioning it favorably against other liquid biopsy or imaging-based recurrence monitoring methods.
• The gross margin of 13.2% is significantly lower than the prior year's 34.0% and is likely below industry averages for mature diagnostic companies, reflecting the company's investment phase and the costs associated with unreimbursed clinical tests as it awaits broader coverage.
• The reduction in full-year revenue guidance, particularly for reimbursed clinical tests, indicates challenges in achieving commercial milestones as quickly as initially projected, a common hurdle for innovative diagnostic companies navigating complex reimbursement landscapes.

Related Party Transactions

• Related party revenue of $1.1 million for the three months ended September 30, 2025, and $3.5 million for the nine months ended September 30, 2025.
• Related party sales and marketing expenses of $1.2 million for the three months ended September 30, 2025, and $2.7 million for the nine months ended September 30, 2025.
• Related party accounts receivable of $2.6 million as of September 30, 2025.
• Related party liabilities of $4.6 million (current) and $1.1 million (long-term) as of September 30, 2025.
• In Q3 2024, a $26.0 million non-cash expense was incurred from Tempus Warrants.

Stakeholder Impact

• Shareholders face negative impact due to significant revenue decline, reduced full-year guidance, lower gross margins, and continued net losses. The increase in weighted-average shares outstanding also dilutes per-share metrics.
• Customers (Physicians/Patients) benefit from strong clinical test volume growth and compelling clinical data supporting the NeXT Personal platform's efficacy in cancer monitoring and recurrence detection.
• Biopharma Partners see continued collaboration and positive clinical trial data (e.g., AstraZeneca) suggesting ongoing value, but risks related to timing of orders and sample receipts remain.
• Employees may experience ongoing strategic focus due to continued investment in driving clinical use and R&D, but financial performance could impact future stability.
• Creditors may note ongoing operational burn from cash usage and net losses, which could be a concern if not offset by future revenue growth and reimbursement.

Next Steps

• Continue efforts to secure Medicare coverage for pending indications, including the recently submitted third dossier for lung cancer.
• Advance the CATE clinical trial in collaboration with Yale Cancer Center to demonstrate the utility of NeXT Personal in guiding breast cancer treatment decisions.
• Host a conference call on November 4, 2025, to discuss Q3 financial results and plans for the remainder of 2025.
• File the Quarterly Report on Form 10-Q for the quarter ended September 30, 2025, with the SEC.

Key Dates

Recommendation

While Personalis demonstrates strong clinical progress with significant growth in test volume and compelling data for its NeXT Personal platform, the financial results are concerning. The substantial year-over-year revenue decline, sharp drop in gross margin, and reduced full-year guidance, particularly for reimbursed clinical tests, indicate significant commercialization challenges and delays in achieving profitability. The company is in an investment phase, burning cash to drive adoption ahead of reimbursement. The long-term potential of its technology is evident, but the near-term financial headwinds and execution risks, especially around Medicare reimbursement, warrant a cautious 'hold' stance. Investors should monitor progress on reimbursement, gross margin improvement, and sustained clinical adoption before considering a stronger position.

Keywords

Personalis, PSNL, Genomics, Precision Oncology, MRD, Minimal Residual Disease, NeXT Personal, Cancer Monitoring, Clinical Tests, Medicare Coverage, Lung Cancer, Breast Cancer, NeoADAURA, LAURA, CATE Trial, Financial Results, Q3 2025, Revenue, Net Loss, Gross Margin, Biopharma, Diagnostics